Ignite Creation Date:
2025-12-25 @ 4:02 AM
Ignite Modification Date:
2025-12-26 @ 2:56 AM
Study NCT ID:
NCT04908202
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-24
First Post:
2021-05-28
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2025-09-17', 'type': 'ESTIMATED'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D015535', 'term': 'Arthritis, Psoriatic'}, {'id': 'D007592', 'term': 'Joint Diseases'}], 'ancestors': [{'id': 'D025242', 'term': 'Spondylarthropathies'}, {'id': 'D025241', 'term': 'Spondylarthritis'}, {'id': 'D013166', 'term': 'Spondylitis'}, {'id': 'D013122', 'term': 'Spinal Diseases'}, {'id': 'D001847', 'term': 'Bone Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D011565', 'term': 'Psoriasis'}, {'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000628674', 'term': 'deucravacitinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'Clinical.Trials@bms.com', 'phone': 'Please email', 'title': 'Bristol-Myers Squibb Study Director', 'organization': 'Bristol-Myers Squibb'}, 'certainAgreement': {'otherDetails': "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'All-cause mortality and Adverse events were collected from first dose (Day 1) and up to 30 days after the last dose of treatment in the study (up to approximately 164 weeks)', 'description': 'All-cause mortality was collected for all the randomized participants and adverse events were collected for all the treated participants.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.', 'otherNumAtRisk': 332, 'deathsNumAtRisk': 336, 'otherNumAffected': 39, 'seriousNumAtRisk': 332, 'deathsNumAffected': 0, 'seriousNumAffected': 6}, {'id': 'EG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.', 'otherNumAtRisk': 333, 'deathsNumAtRisk': 334, 'otherNumAffected': 32, 'seriousNumAtRisk': 333, 'deathsNumAffected': 0, 'seriousNumAffected': 8}, {'id': 'EG002', 'title': 'Active Treatment Period - Deucravacitinib 6 mg QD', 'description': 'Participants earlier randomized to Deucravacitinib 6 mg QD arm in Placebo-Controlled period continued to receive 6 mg deucravacitinib tablet orally QD till Week 52 during Active Treatment period.', 'otherNumAtRisk': 309, 'deathsNumAtRisk': 309, 'otherNumAffected': 68, 'seriousNumAtRisk': 309, 'deathsNumAffected': 0, 'seriousNumAffected': 21}, {'id': 'EG003', 'title': 'Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD', 'description': 'Participants earlier randomized to Placebo arm in Placebo-Controlled period received 6 mg deucravacitinib tablet orally QD till Week 52 during Active Treatment period.', 'otherNumAtRisk': 306, 'deathsNumAtRisk': 306, 'otherNumAffected': 67, 'seriousNumAtRisk': 306, 'deathsNumAffected': 0, 'seriousNumAffected': 17}], 'otherEvents': [{'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 24}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 26}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 32}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 33}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 18}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 14}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}], 'seriousEvents': [{'term': 'Lymphadenitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Angina unstable', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Sinus node dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Iridocyclitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Hiatus hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Inguinal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Small intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Alcoholic liver disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Drug hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'COVID-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Hepatitis infectious mononucleosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Herpes zoster disseminated', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Renal cyst infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Soft tissue infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Vulval cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Compression fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Humerus fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Meniscus injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Radius fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Traumatic fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Wrist fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Blood glucose increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Diabetic metabolic decompensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Musculoskeletal stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Osteonecrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Endometrial cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Glioblastoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Prostate cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Cerebral haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Embolic stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Hallucination', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Major depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Psychotic disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Vaginal haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 332, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 333, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 309, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 306, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 28'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With ACR 20 Response at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '54.2', 'groupId': 'OG000', 'lowerLimit': '48.7', 'upperLimit': '59.6'}, {'value': '34.1', 'groupId': 'OG001', 'lowerLimit': '29.1', 'upperLimit': '39.5'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.29', 'ciLowerLimit': '1.67', 'ciUpperLimit': '3.13', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '317', 'groupId': 'OG000'}, {'value': '317', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.4106', 'spread': '1.13277', 'groupId': 'OG000'}, {'value': '-0.8902', 'spread': '1.10750', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'ADJUSTED MEAN DIFFERENCE', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.5051', 'ciLowerLimit': '-0.6709', 'ciUpperLimit': '-0.3392', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.4103', 'spread': '0.52303', 'groupId': 'OG000'}, {'value': '-0.2118', 'spread': '0.51583', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'ADJUSTED MEAN DIFFERENCE', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.1688', 'ciLowerLimit': '-0.2442', 'ciUpperLimit': '-0.0933', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 16', 'description': 'HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'OG000'}, {'value': '170', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '51.9', 'groupId': 'OG000', 'lowerLimit': '43.9', 'upperLimit': '59.8'}, {'value': '7.1', 'groupId': 'OG001', 'lowerLimit': '3.7', 'upperLimit': '12.0'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '14.08', 'ciLowerLimit': '7.19', 'ciUpperLimit': '27.59', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Randomized population with participants with at least 3% body surface area (BSA) Involvement and at least static Physician's Global Assessment (sPGA) 2 at baseline"}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.410', 'spread': '8.2883', 'groupId': 'OG000'}, {'value': '3.847', 'spread': '7.2929', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'ADJUSTED MEAN DIFFERENCE', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.631', 'ciLowerLimit': '3.481', 'ciUpperLimit': '9.781', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '178', 'groupId': 'OG000'}, {'value': '167', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '48.3', 'groupId': 'OG000', 'lowerLimit': '40.8', 'upperLimit': '55.9'}, {'value': '46.1', 'groupId': 'OG001', 'lowerLimit': '38.4', 'upperLimit': '54.0'}]}]}], 'analyses': [{'pValue': '0.5699', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.13', 'ciLowerLimit': '0.74', 'ciUpperLimit': '1.75', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population with Enthesitis at Baseline by LEI'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '19.0', 'groupId': 'OG000', 'lowerLimit': '15.0', 'upperLimit': '23.7'}, {'value': '10.2', 'groupId': 'OG001', 'lowerLimit': '7.2', 'upperLimit': '13.9'}]}]}], 'analyses': [{'pValue': '0.0012', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.08', 'ciLowerLimit': '1.33', 'ciUpperLimit': '3.26', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:\n\n1. Tender joint count \\<= 1\n2. Swollen joint count \\<=1\n3. Psoriasis Area and Severity Index (PASI) \\<= 1 or body surface area (BSA) \\<= 3%\n4. Patient assessment of psoriatic arthiritis (PsA) pain \\<= 15\n5. Patient Global Assessment of PsA disease activity \\<= 20\n6. HAQ-DI \\<= 0.5\n7. Tender enthesial points \\<= 1', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with available data at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.9', 'spread': '8.84', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '8.81', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'ADJUSTED MEAN DIFFERENCE', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.6', 'ciLowerLimit': '1.4', 'ciUpperLimit': '3.9', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 16', 'description': 'FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one\'s ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Dactylitis Resolution at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '108', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '59.1', 'groupId': 'OG000', 'lowerLimit': '50.2', 'upperLimit': '67.6'}, {'value': '43.5', 'groupId': 'OG001', 'lowerLimit': '34.0', 'upperLimit': '53.4'}]}]}], 'analyses': [{'pValue': '0.0270', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.80', 'ciLowerLimit': '1.07', 'ciUpperLimit': '3.03', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with tender dactylitis count \\>=1 at baseline were included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '245', 'groupId': 'OG000'}, {'value': '251', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.3980', 'spread': '2.00852', 'groupId': 'OG000'}, {'value': '0.5757', 'spread': '2.73874', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.7194', 'groupIds': ['OG000', 'OG001'], 'paramType': 'ADJUSTED MEAN DIFFERENCE', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.1596', 'ciLowerLimit': '-0.7114', 'ciUpperLimit': '1.0306', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With ACR 20 Response up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '14.0', 'groupId': 'OG000', 'lowerLimit': '10.5', 'upperLimit': '18.2'}, {'value': '13.8', 'groupId': 'OG001', 'lowerLimit': '10.3', 'upperLimit': '17.9'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '31.5', 'groupId': 'OG000', 'lowerLimit': '26.6', 'upperLimit': '36.8'}, {'value': '19.5', 'groupId': 'OG001', 'lowerLimit': '15.4', 'upperLimit': '24.1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '42.6', 'groupId': 'OG000', 'lowerLimit': '37.2', 'upperLimit': '48.0'}, {'value': '30.5', 'groupId': 'OG001', 'lowerLimit': '25.6', 'upperLimit': '35.8'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '49.1', 'groupId': 'OG000', 'lowerLimit': '43.6', 'upperLimit': '54.6'}, {'value': '31.1', 'groupId': 'OG001', 'lowerLimit': '26.2', 'upperLimit': '36.4'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '54.2', 'groupId': 'OG000', 'lowerLimit': '48.7', 'upperLimit': '59.6'}, {'value': '34.1', 'groupId': 'OG001', 'lowerLimit': '29.1', 'upperLimit': '39.5'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12, and 16', 'description': 'The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With ACR 50 Response up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '2.1', 'groupId': 'OG000', 'lowerLimit': '0.8', 'upperLimit': '4.2'}, {'value': '1.2', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '3.0'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '7.7', 'groupId': 'OG000', 'lowerLimit': '5.1', 'upperLimit': '11.1'}, {'value': '3.6', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '6.2'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '17.0', 'groupId': 'OG000', 'lowerLimit': '13.1', 'upperLimit': '21.4'}, {'value': '9.6', 'groupId': 'OG001', 'lowerLimit': '6.6', 'upperLimit': '13.3'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '22.6', 'groupId': 'OG000', 'lowerLimit': '18.3', 'upperLimit': '27.5'}, {'value': '10.8', 'groupId': 'OG001', 'lowerLimit': '7.7', 'upperLimit': '14.6'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '24.7', 'groupId': 'OG000', 'lowerLimit': '20.2', 'upperLimit': '29.7'}, {'value': '13.5', 'groupId': 'OG001', 'lowerLimit': '10.0', 'upperLimit': '17.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12, and 16', 'description': 'The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With ACR 70 Response up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '0.3', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '1.6'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '1.1'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '1.8', 'groupId': 'OG000', 'lowerLimit': '0.7', 'upperLimit': '3.8'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '1.1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '5.7', 'groupId': 'OG000', 'lowerLimit': '3.4', 'upperLimit': '8.7'}, {'value': '3.0', 'groupId': 'OG001', 'lowerLimit': '1.4', 'upperLimit': '5.4'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '7.4', 'groupId': 'OG000', 'lowerLimit': '4.9', 'upperLimit': '10.8'}, {'value': '3.6', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '6.2'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '11.6', 'groupId': 'OG000', 'lowerLimit': '8.4', 'upperLimit': '15.5'}, {'value': '5.4', 'groupId': 'OG001', 'lowerLimit': '3.2', 'upperLimit': '8.4'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12, and 16', 'description': 'The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '327', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2 (n=324, 323)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '324', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.1655', 'spread': '0.37744', 'groupId': 'OG000'}, {'value': '-0.1250', 'spread': '0.38243', 'groupId': 'OG001'}]}]}, {'title': 'Week 4 (n=325, 326)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.2412', 'spread': '0.43862', 'groupId': 'OG000'}, {'value': '-0.1614', 'spread': '0.39402', 'groupId': 'OG001'}]}]}, {'title': 'Week 8 (n=327, 326)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '327', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.3119', 'spread': '0.50219', 'groupId': 'OG000'}, {'value': '-0.1963', 'spread': '0.47057', 'groupId': 'OG001'}]}]}, {'title': 'Week 12 (n= 326, 327)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.3589', 'spread': '0.49384', 'groupId': 'OG000'}, {'value': '-0.1957', 'spread': '0.53080', 'groupId': 'OG001'}]}]}, {'title': 'Week 16 (n=326, 327)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.4103', 'spread': '0.52303', 'groupId': 'OG000'}, {'value': '-0.2118', 'spread': '0.51583', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 2, 4, 8, 12, and 16', 'description': 'HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '314', 'groupId': 'OG000'}, {'value': '307', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '28.0', 'groupId': 'OG000', 'lowerLimit': '23.1', 'upperLimit': '33.3'}, {'value': '28.0', 'groupId': 'OG001', 'lowerLimit': '23.1', 'upperLimit': '33.4'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '41.4', 'groupId': 'OG000', 'lowerLimit': '35.9', 'upperLimit': '47.1'}, {'value': '30.9', 'groupId': 'OG001', 'lowerLimit': '25.8', 'upperLimit': '36.4'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '45.5', 'groupId': 'OG000', 'lowerLimit': '39.9', 'upperLimit': '51.2'}, {'value': '34.2', 'groupId': 'OG001', 'lowerLimit': '28.9', 'upperLimit': '39.8'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '49.7', 'groupId': 'OG000', 'lowerLimit': '44.0', 'upperLimit': '55.4'}, {'value': '39.7', 'groupId': 'OG001', 'lowerLimit': '34.2', 'upperLimit': '45.5'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '51.3', 'groupId': 'OG000', 'lowerLimit': '45.6', 'upperLimit': '56.9'}, {'value': '38.8', 'groupId': 'OG001', 'lowerLimit': '33.3', 'upperLimit': '44.5'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline and Week 2, 4, 8, 12, and 16', 'description': 'HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.', 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with a HAQ-DI score ≥0.35 at Baseline were included in the analysis.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'OG000'}, {'value': '170', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '11.7', 'groupId': 'OG000', 'lowerLimit': '7.2', 'upperLimit': '17.7'}, {'value': '6.5', 'groupId': 'OG001', 'lowerLimit': '3.3', 'upperLimit': '11.3'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '31.5', 'groupId': 'OG000', 'lowerLimit': '24.4', 'upperLimit': '39.2'}, {'value': '10.0', 'groupId': 'OG001', 'lowerLimit': '5.9', 'upperLimit': '15.5'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '42.6', 'groupId': 'OG000', 'lowerLimit': '34.9', 'upperLimit': '50.6'}, {'value': '8.8', 'groupId': 'OG001', 'lowerLimit': '5.0', 'upperLimit': '14.1'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '51.9', 'groupId': 'OG000', 'lowerLimit': '43.9', 'upperLimit': '59.8'}, {'value': '7.1', 'groupId': 'OG001', 'lowerLimit': '3.7', 'upperLimit': '12.0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Randomized population with participants with at least 3% body surface area (BSA) Involvement and at least static Physician's Global Assessment (sPGA) 2 at baseline"}, {'type': 'SECONDARY', 'title': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'OG000'}, {'value': '170', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '4.3', 'groupId': 'OG000', 'lowerLimit': '1.8', 'upperLimit': '8.7'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.4', 'upperLimit': '5.1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '14.8', 'groupId': 'OG000', 'lowerLimit': '9.7', 'upperLimit': '21.2'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.4', 'upperLimit': '5.1'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '20.4', 'groupId': 'OG000', 'lowerLimit': '14.5', 'upperLimit': '27.4'}, {'value': '3.5', 'groupId': 'OG001', 'lowerLimit': '1.3', 'upperLimit': '7.5'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '25.3', 'groupId': 'OG000', 'lowerLimit': '18.8', 'upperLimit': '32.7'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.4', 'upperLimit': '5.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Randomized population with participants with at least 3% body surface area (BSA) Involvement and at least static Physician's Global Assessment (sPGA) 2 at baseline"}, {'type': 'SECONDARY', 'title': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'denoms': [{'units': 'Participants', 'counts': [{'value': '162', 'groupId': 'OG000'}, {'value': '170', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '1.9', 'groupId': 'OG000', 'lowerLimit': '0.4', 'upperLimit': '5.3'}, {'value': '1.2', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '4.2'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '8.0', 'groupId': 'OG000', 'lowerLimit': '4.3', 'upperLimit': '13.3'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '3.2'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000', 'lowerLimit': '6.7', 'upperLimit': '17.0'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.4', 'upperLimit': '5.1'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '14.2', 'groupId': 'OG000', 'lowerLimit': '9.2', 'upperLimit': '20.5'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.4', 'upperLimit': '5.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "Randomized population with participants with at least 3% body surface area (BSA) Involvement and at least static Physician's Global Assessment (sPGA) 2 at baseline"}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.760', 'spread': '6.2768', 'groupId': 'OG000'}, {'value': '3.326', 'spread': '5.7315', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.021', 'spread': '7.5809', 'groupId': 'OG000'}, {'value': '3.916', 'spread': '7.6614', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.410', 'spread': '8.2883', 'groupId': 'OG000'}, {'value': '3.847', 'spread': '7.2929', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '178', 'groupId': 'OG000'}, {'value': '167', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '31.5', 'groupId': 'OG000', 'lowerLimit': '24.7', 'upperLimit': '38.8'}, {'value': '32.9', 'groupId': 'OG001', 'lowerLimit': '25.9', 'upperLimit': '40.6'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '44.4', 'groupId': 'OG000', 'lowerLimit': '37.0', 'upperLimit': '52.0'}, {'value': '47.9', 'groupId': 'OG001', 'lowerLimit': '40.1', 'upperLimit': '55.8'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '47.2', 'groupId': 'OG000', 'lowerLimit': '39.7', 'upperLimit': '54.8'}, {'value': '50.3', 'groupId': 'OG001', 'lowerLimit': '42.5', 'upperLimit': '58.1'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '48.3', 'groupId': 'OG000', 'lowerLimit': '40.8', 'upperLimit': '55.9'}, {'value': '46.1', 'groupId': 'OG001', 'lowerLimit': '38.4', 'upperLimit': '54.0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population with Enthesitis at Baseline by LEI'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '216', 'groupId': 'OG000'}, {'value': '211', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '19.4', 'groupId': 'OG000', 'lowerLimit': '14.4', 'upperLimit': '25.4'}, {'value': '25.6', 'groupId': 'OG001', 'lowerLimit': '19.8', 'upperLimit': '32.0'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '34.7', 'groupId': 'OG000', 'lowerLimit': '28.4', 'upperLimit': '41.5'}, {'value': '30.8', 'groupId': 'OG001', 'lowerLimit': '24.6', 'upperLimit': '37.5'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '36.6', 'groupId': 'OG000', 'lowerLimit': '30.1', 'upperLimit': '43.4'}, {'value': '34.6', 'groupId': 'OG001', 'lowerLimit': '28.2', 'upperLimit': '41.4'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '45.8', 'groupId': 'OG000', 'lowerLimit': '39.1', 'upperLimit': '52.7'}, {'value': '34.1', 'groupId': 'OG001', 'lowerLimit': '27.8', 'upperLimit': '40.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \\\\\\[R\\\\\\]/left \\\\\\[L\\\\\\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population with Enthesitis at Baseline by SPARCC'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '6.0', 'groupId': 'OG000', 'lowerLimit': '3.7', 'upperLimit': '9.0'}, {'value': '3.0', 'groupId': 'OG001', 'lowerLimit': '1.4', 'upperLimit': '5.4'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '10.1', 'groupId': 'OG000', 'lowerLimit': '7.1', 'upperLimit': '13.9'}, {'value': '6.6', 'groupId': 'OG001', 'lowerLimit': '4.2', 'upperLimit': '9.8'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '14.0', 'groupId': 'OG000', 'lowerLimit': '10.5', 'upperLimit': '18.2'}, {'value': '7.2', 'groupId': 'OG001', 'lowerLimit': '4.7', 'upperLimit': '10.5'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '19.0', 'groupId': 'OG000', 'lowerLimit': '15.0', 'upperLimit': '23.7'}, {'value': '10.2', 'groupId': 'OG001', 'lowerLimit': '7.2', 'upperLimit': '13.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, 8, 12, and 16', 'description': 'Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:\n\n1. Tender joint count \\<= 1\n2. Swollen joint count \\<=1\n3. Psoriasis Area and Severity Index (PASI) \\<= 1 or body surface area (BSA) \\<= 3%\n4. Patient assessment of psoriatic arthiritis (PsA) pain \\<= 15\n5. Patient Global Assessment of PsA disease activity \\<= 20\n6. HAQ-DI \\<= 0.5\n7. Tender enthesial points \\<= 1', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.814', 'spread': '7.5082', 'groupId': 'OG000'}, {'value': '0.634', 'spread': '7.3796', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.056', 'spread': '8.4206', 'groupId': 'OG000'}, {'value': '0.034', 'spread': '8.3926', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.588', 'spread': '8.3442', 'groupId': 'OG000'}, {'value': '0.358', 'spread': '8.1559', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '327', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '324', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.2', 'spread': '7.31', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '6.52', 'groupId': 'OG001'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.5', 'spread': '7.48', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '7.67', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '327', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.5', 'spread': '8.68', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '9.64', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.3', 'spread': '8.98', 'groupId': 'OG000'}, {'value': '1.8', 'spread': '8.97', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.9', 'spread': '8.84', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '8.81', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one\'s ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Dactylitis Resolution up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '132', 'groupId': 'OG000'}, {'value': '108', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '36.4', 'groupId': 'OG000', 'lowerLimit': '28.2', 'upperLimit': '45.2'}, {'value': '33.3', 'groupId': 'OG001', 'lowerLimit': '24.6', 'upperLimit': '43.1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '44.7', 'groupId': 'OG000', 'lowerLimit': '36.0', 'upperLimit': '53.6'}, {'value': '43.5', 'groupId': 'OG001', 'lowerLimit': '34.0', 'upperLimit': '53.4'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '54.5', 'groupId': 'OG000', 'lowerLimit': '45.7', 'upperLimit': '63.2'}, {'value': '48.1', 'groupId': 'OG001', 'lowerLimit': '38.4', 'upperLimit': '58.0'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '59.1', 'groupId': 'OG000', 'lowerLimit': '50.2', 'upperLimit': '67.6'}, {'value': '43.5', 'groupId': 'OG001', 'lowerLimit': '34.0', 'upperLimit': '53.4'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with tender dactylitis count \\>=1 at baseline were included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '327', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '324', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.807', 'spread': '1.3327', 'groupId': 'OG000'}, {'value': '-0.652', 'spread': '1.2524', 'groupId': 'OG001'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.164', 'spread': '1.5433', 'groupId': 'OG000'}, {'value': '-0.836', 'spread': '1.5580', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '327', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.545', 'spread': '1.9037', 'groupId': 'OG000'}, {'value': '-0.991', 'spread': '1.9281', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.761', 'spread': '2.0074', 'groupId': 'OG000'}, {'value': '-0.883', 'spread': '1.9677', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.851', 'spread': '2.0440', 'groupId': 'OG000'}, {'value': '-1.015', 'spread': '1.9955', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '322', 'groupId': 'OG000'}, {'value': '318', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-7.6211', 'spread': '13.23221', 'groupId': 'OG000'}, {'value': '-7.0045', 'spread': '11.71166', 'groupId': 'OG001'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '324', 'groupId': 'OG000'}, {'value': '321', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-12.5643', 'spread': '14.38734', 'groupId': 'OG000'}, {'value': '-10.1201', 'spread': '13.64766', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-16.6770', 'spread': '16.71038', 'groupId': 'OG000'}, {'value': '-12.3610', 'spread': '15.70632', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '323', 'groupId': 'OG000'}, {'value': '321', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-19.8346', 'spread': '17.22613', 'groupId': 'OG000'}, {'value': '-13.2671', 'spread': '17.41524', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '317', 'groupId': 'OG000'}, {'value': '317', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-20.7263', 'spread': '18.08249', 'groupId': 'OG000'}, {'value': '-13.4075', 'spread': '17.31116', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\\\\[cm\\\\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '6.5', 'groupId': 'OG000', 'lowerLimit': '4.1', 'upperLimit': '9.7'}, {'value': '4.5', 'groupId': 'OG001', 'lowerLimit': '2.5', 'upperLimit': '7.3'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '13.7', 'groupId': 'OG000', 'lowerLimit': '10.2', 'upperLimit': '17.8'}, {'value': '9.9', 'groupId': 'OG001', 'lowerLimit': '6.9', 'upperLimit': '13.6'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '21.4', 'groupId': 'OG000', 'lowerLimit': '17.2', 'upperLimit': '26.2'}, {'value': '16.5', 'groupId': 'OG001', 'lowerLimit': '12.7', 'upperLimit': '20.9'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '28.9', 'groupId': 'OG000', 'lowerLimit': '24.1', 'upperLimit': '34.0'}, {'value': '17.4', 'groupId': 'OG001', 'lowerLimit': '13.5', 'upperLimit': '21.9'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '26.2', 'groupId': 'OG000', 'lowerLimit': '21.6', 'upperLimit': '31.2'}, {'value': '18.9', 'groupId': 'OG001', 'lowerLimit': '14.8', 'upperLimit': '23.5'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\\\\[cm\\\\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '0.3', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '1.6'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '1.1'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000', 'lowerLimit': '0.5', 'upperLimit': '3.4'}, {'value': '0.6', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '2.1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '3.0', 'groupId': 'OG000', 'lowerLimit': '1.4', 'upperLimit': '5.4'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.7', 'upperLimit': '3.9'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '5.7', 'groupId': 'OG000', 'lowerLimit': '3.4', 'upperLimit': '8.7'}, {'value': '1.8', 'groupId': 'OG001', 'lowerLimit': '0.7', 'upperLimit': '3.9'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '8.6', 'groupId': 'OG000', 'lowerLimit': '5.9', 'upperLimit': '12.2'}, {'value': '2.7', 'groupId': 'OG001', 'lowerLimit': '1.2', 'upperLimit': '5.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\\\\[cm\\\\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '12.7', 'groupId': 'OG000', 'lowerLimit': '6.0', 'upperLimit': '22.7'}, {'value': '6.6', 'groupId': 'OG001', 'lowerLimit': '1.8', 'upperLimit': '15.9'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '19.7', 'groupId': 'OG000', 'lowerLimit': '11.2', 'upperLimit': '30.9'}, {'value': '16.4', 'groupId': 'OG001', 'lowerLimit': '8.2', 'upperLimit': '28.1'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '16.9', 'groupId': 'OG000', 'lowerLimit': '9.0', 'upperLimit': '27.7'}, {'value': '21.3', 'groupId': 'OG001', 'lowerLimit': '11.9', 'upperLimit': '33.7'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '23.9', 'groupId': 'OG000', 'lowerLimit': '14.6', 'upperLimit': '35.5'}, {'value': '14.8', 'groupId': 'OG001', 'lowerLimit': '7.0', 'upperLimit': '26.2'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with a baseline PGA-F score of ≥3'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '322', 'groupId': 'OG000'}, {'value': '318', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.4028', 'spread': '0.77126', 'groupId': 'OG000'}, {'value': '-0.4006', 'spread': '0.70508', 'groupId': 'OG001'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '324', 'groupId': 'OG000'}, {'value': '321', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.7655', 'spread': '0.90092', 'groupId': 'OG000'}, {'value': '-0.6468', 'spread': '0.82146', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.0820', 'spread': '1.02041', 'groupId': 'OG000'}, {'value': '-0.7727', 'spread': '0.99752', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '323', 'groupId': 'OG000'}, {'value': '321', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.3360', 'spread': '1.13745', 'groupId': 'OG000'}, {'value': '-0.8450', 'spread': '1.09776', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '317', 'groupId': 'OG000'}, {'value': '317', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.4106', 'spread': '1.13277', 'groupId': 'OG000'}, {'value': '-0.8902', 'spread': '1.10750', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\\\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\\\\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '5.4', 'groupId': 'OG000', 'lowerLimit': '3.2', 'upperLimit': '8.3'}, {'value': '4.8', 'groupId': 'OG001', 'lowerLimit': '2.8', 'upperLimit': '7.7'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '9.8', 'groupId': 'OG000', 'lowerLimit': '6.9', 'upperLimit': '13.5'}, {'value': '6.0', 'groupId': 'OG001', 'lowerLimit': '3.7', 'upperLimit': '9.1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '11.3', 'groupId': 'OG000', 'lowerLimit': '8.1', 'upperLimit': '15.2'}, {'value': '9.3', 'groupId': 'OG001', 'lowerLimit': '6.4', 'upperLimit': '12.9'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000', 'lowerLimit': '10.7', 'upperLimit': '18.5'}, {'value': '11.7', 'groupId': 'OG001', 'lowerLimit': '8.4', 'upperLimit': '15.6'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '15.2', 'groupId': 'OG000', 'lowerLimit': '11.5', 'upperLimit': '19.5'}, {'value': '8.1', 'groupId': 'OG001', 'lowerLimit': '5.4', 'upperLimit': '11.5'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\\\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\\\\>5.1=high disease activity.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '2.1', 'groupId': 'OG000', 'lowerLimit': '0.8', 'upperLimit': '4.2'}, {'value': '2.1', 'groupId': 'OG001', 'lowerLimit': '0.8', 'upperLimit': '4.3'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '8.0', 'groupId': 'OG000', 'lowerLimit': '5.4', 'upperLimit': '11.5'}, {'value': '5.4', 'groupId': 'OG001', 'lowerLimit': '3.2', 'upperLimit': '8.4'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '14.9', 'groupId': 'OG000', 'lowerLimit': '11.3', 'upperLimit': '19.1'}, {'value': '8.7', 'groupId': 'OG001', 'lowerLimit': '5.9', 'upperLimit': '12.2'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '20.8', 'groupId': 'OG000', 'lowerLimit': '16.6', 'upperLimit': '25.6'}, {'value': '9.0', 'groupId': 'OG001', 'lowerLimit': '6.1', 'upperLimit': '12.6'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '22.3', 'groupId': 'OG000', 'lowerLimit': '18.0', 'upperLimit': '27.2'}, {'value': '13.8', 'groupId': 'OG001', 'lowerLimit': '10.3', 'upperLimit': '17.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\\\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\\\\>5.1=high disease activity.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '317', 'groupId': 'OG000'}, {'value': '316', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '317', 'groupId': 'OG000'}, {'value': '316', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.0405', 'spread': '1.03004', 'groupId': 'OG000'}, {'value': '-0.8258', 'spread': '0.97038', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '314', 'groupId': 'OG000'}, {'value': '315', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.7675', 'spread': '1.37563', 'groupId': 'OG000'}, {'value': '-1.0780', 'spread': '1.33036', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '313', 'groupId': 'OG000'}, {'value': '314', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.9064', 'spread': '1.45258', 'groupId': 'OG000'}, {'value': '-1.1026', 'spread': '1.31166', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '323', 'groupId': 'OG000'}, {'value': '322', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '1.81', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '1.61', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '2.09', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '1.89', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '324', 'groupId': 'OG000'}, {'value': '323', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.1', 'spread': '2.16', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '2.01', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '323', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '2.22', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '1.96', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 8, 12 and 16', 'description': 'Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '25.9', 'groupId': 'OG000', 'lowerLimit': '21.3', 'upperLimit': '30.9'}, {'value': '21.9', 'groupId': 'OG001', 'lowerLimit': '17.5', 'upperLimit': '26.7'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '47.0', 'groupId': 'OG000', 'lowerLimit': '41.6', 'upperLimit': '52.5'}, {'value': '31.1', 'groupId': 'OG001', 'lowerLimit': '26.2', 'upperLimit': '36.4'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '51.5', 'groupId': 'OG000', 'lowerLimit': '46.0', 'upperLimit': '56.9'}, {'value': '41.3', 'groupId': 'OG001', 'lowerLimit': '36.0', 'upperLimit': '46.8'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '55.4', 'groupId': 'OG000', 'lowerLimit': '49.9', 'upperLimit': '60.8'}, {'value': '39.8', 'groupId': 'OG001', 'lowerLimit': '34.5', 'upperLimit': '45.3'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '62.5', 'groupId': 'OG000', 'lowerLimit': '57.1', 'upperLimit': '67.7'}, {'value': '40.1', 'groupId': 'OG001', 'lowerLimit': '34.8', 'upperLimit': '45.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': "The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity", 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'value': '7.3', 'groupId': 'OG000', 'lowerLimit': '2.0', 'upperLimit': '17.6'}, {'value': '6.1', 'groupId': 'OG001', 'lowerLimit': '1.3', 'upperLimit': '16.9'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'value': '10.9', 'groupId': 'OG000', 'lowerLimit': '4.1', 'upperLimit': '22.2'}, {'value': '16.3', 'groupId': 'OG001', 'lowerLimit': '7.3', 'upperLimit': '29.7'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '18.2', 'groupId': 'OG000', 'lowerLimit': '9.1', 'upperLimit': '30.9'}, {'value': '14.3', 'groupId': 'OG001', 'lowerLimit': '5.9', 'upperLimit': '27.2'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '25.5', 'groupId': 'OG000', 'lowerLimit': '14.7', 'upperLimit': '39.0'}, {'value': '16.3', 'groupId': 'OG001', 'lowerLimit': '7.3', 'upperLimit': '29.7'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '25.5', 'groupId': 'OG000', 'lowerLimit': '14.7', 'upperLimit': '39.0'}, {'value': '14.3', 'groupId': 'OG001', 'lowerLimit': '5.9', 'upperLimit': '27.2'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed. with spondylitis in addition to peripheral joint involvement as their presentation of PsA were included in the analysis.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '59.5', 'groupId': 'OG000', 'lowerLimit': '54.1', 'upperLimit': '64.8'}, {'value': '53.9', 'groupId': 'OG001', 'lowerLimit': '48.4', 'upperLimit': '59.3'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '62.8', 'groupId': 'OG000', 'lowerLimit': '57.4', 'upperLimit': '68.0'}, {'value': '60.5', 'groupId': 'OG001', 'lowerLimit': '55.0', 'upperLimit': '65.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '67.6', 'groupId': 'OG000', 'lowerLimit': '62.3', 'upperLimit': '72.5'}, {'value': '66.2', 'groupId': 'OG001', 'lowerLimit': '60.8', 'upperLimit': '71.2'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\\* standard deviation of the paired differences of change from baseline/ square root of (2\\*k); k is the number of reviewers and is default to 2 in this study.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '60.4', 'groupId': 'OG000', 'lowerLimit': '55.0', 'upperLimit': '65.7'}, {'value': '56.6', 'groupId': 'OG001', 'lowerLimit': '51.1', 'upperLimit': '62.0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '64.3', 'groupId': 'OG000', 'lowerLimit': '58.9', 'upperLimit': '69.4'}, {'value': '62.9', 'groupId': 'OG001', 'lowerLimit': '57.4', 'upperLimit': '68.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '66.7', 'groupId': 'OG000', 'lowerLimit': '61.3', 'upperLimit': '71.7'}, {'value': '66.8', 'groupId': 'OG001', 'lowerLimit': '61.4', 'upperLimit': '71.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\\* standard deviation of the paired differences of change from baseline/ square root of (2\\*k); k is the number of reviewers and is default to 2 in this study.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '67.6', 'groupId': 'OG000', 'lowerLimit': '62.3', 'upperLimit': '72.5'}, {'value': '64.4', 'groupId': 'OG001', 'lowerLimit': '59.0', 'upperLimit': '69.5'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '70.5', 'groupId': 'OG000', 'lowerLimit': '65.3', 'upperLimit': '75.4'}, {'value': '68.9', 'groupId': 'OG001', 'lowerLimit': '63.6', 'upperLimit': '73.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'OG000'}, {'value': '334', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '70.5', 'groupId': 'OG000', 'lowerLimit': '65.3', 'upperLimit': '75.4'}, {'value': '68.9', 'groupId': 'OG001', 'lowerLimit': '63.6', 'upperLimit': '73.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\\* standard deviation of the paired differences of change from baseline/ square root of (2\\*k); k is the number of reviewers and is default to 2 in this study.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '245', 'groupId': 'OG000'}, {'value': '251', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.32', 'spread': '1.417', 'groupId': 'OG000'}, {'value': '0.37', 'spread': '1.326', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '245', 'groupId': 'OG000'}, {'value': '251', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.09', 'spread': '0.703', 'groupId': 'OG000'}, {'value': '0.14', 'spread': '0.485', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.923', 'spread': '17.9483', 'groupId': 'OG000'}, {'value': '6.908', 'spread': '17.0306', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.615', 'spread': '20.5725', 'groupId': 'OG000'}, {'value': '7.784', 'spread': '22.4709', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '15.414', 'spread': '22.3930', 'groupId': 'OG000'}, {'value': '8.226', 'spread': '22.1449', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.962', 'spread': '20.6963', 'groupId': 'OG000'}, {'value': '7.058', 'spread': '18.7454', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.096', 'spread': '22.7372', 'groupId': 'OG000'}, {'value': '8.365', 'spread': '21.1286', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.152', 'spread': '23.6370', 'groupId': 'OG000'}, {'value': '7.913', 'spread': '20.8035', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '10.0', 'spread': '16.52', 'groupId': 'OG000'}, {'value': '8.5', 'spread': '15.47', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '16.6', 'spread': '20.96', 'groupId': 'OG000'}, {'value': '9.4', 'spread': '19.66', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '18.2', 'spread': '21.83', 'groupId': 'OG000'}, {'value': '10.0', 'spread': '18.85', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.1', 'spread': '12.95', 'groupId': 'OG000'}, {'value': '5.1', 'spread': '13.35', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.4', 'spread': '15.13', 'groupId': 'OG000'}, {'value': '4.8', 'spread': '15.02', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.9', 'spread': '16.00', 'groupId': 'OG000'}, {'value': '4.6', 'spread': '14.85', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.558', 'spread': '14.6829', 'groupId': 'OG000'}, {'value': '4.327', 'spread': '14.3971', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.442', 'spread': '17.9283', 'groupId': 'OG000'}, {'value': '4.308', 'spread': '17.6763', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.682', 'spread': '16.4474', 'groupId': 'OG000'}, {'value': '4.893', 'spread': '17.5265', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.69', 'spread': '20.610', 'groupId': 'OG000'}, {'value': '4.62', 'spread': '20.737', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.96', 'spread': '23.990', 'groupId': 'OG000'}, {'value': '4.88', 'spread': '22.539', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.80', 'spread': '22.960', 'groupId': 'OG000'}, {'value': '4.74', 'spread': '23.303', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '14.17', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '13.99', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.9', 'spread': '16.41', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '16.38', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.5', 'spread': '15.98', 'groupId': 'OG000'}, {'value': '1.5', 'spread': '15.78', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.718', 'spread': '20.1133', 'groupId': 'OG000'}, {'value': '2.128', 'spread': '20.1154', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.846', 'spread': '21.4070', 'groupId': 'OG000'}, {'value': '0.718', 'spread': '21.0925', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '327', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.438', 'spread': '22.6517', 'groupId': 'OG000'}, {'value': '2.370', 'spread': '21.4931', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'WPAI Absenteeism', 'denoms': [{'units': 'Participants', 'counts': [{'value': '167', 'groupId': 'OG000'}, {'value': '157', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.30', 'spread': '20.777', 'groupId': 'OG000'}, {'value': '1.23', 'spread': '19.389', 'groupId': 'OG001'}]}]}, {'title': 'WPAI Presenteeism', 'denoms': [{'units': 'Participants', 'counts': [{'value': '157', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-13.76', 'spread': '23.299', 'groupId': 'OG000'}, {'value': '-6.91', 'spread': '20.332', 'groupId': 'OG001'}]}]}, {'title': 'Work Productivity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '157', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-13.33', 'spread': '24.053', 'groupId': 'OG000'}, {'value': '-6.80', 'spread': '21.526', 'groupId': 'OG001'}]}]}, {'title': 'WPAI Activity Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-15.20', 'spread': '25.466', 'groupId': 'OG000'}, {'value': '-9.69', 'spread': '23.855', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and week 16', 'description': 'WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Utility Score (Week 4)', 'categories': [{'measurements': [{'value': '0.1006', 'spread': '0.19470', 'groupId': 'OG000'}, {'value': '0.0694', 'spread': '0.19282', 'groupId': 'OG001'}]}]}, {'title': 'Utility Score (Week 16)', 'categories': [{'measurements': [{'value': '0.1630', 'spread': '0.23696', 'groupId': 'OG000'}, {'value': '0.0721', 'spread': '0.23083', 'groupId': 'OG001'}]}]}, {'title': 'Mobility (Week 4)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.77', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.80', 'groupId': 'OG001'}]}]}, {'title': 'Mobility (Week 16)', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.88', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.92', 'groupId': 'OG001'}]}]}, {'title': 'Self-Care (Week 4)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.81', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '0.78', 'groupId': 'OG001'}]}]}, {'title': 'Self-Care (Week 16)', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.90', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '0.86', 'groupId': 'OG001'}]}]}, {'title': 'Usual Activities (Week 4)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.83', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.71', 'groupId': 'OG001'}]}]}, {'title': 'Usual Activities (Week 16)', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.92', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.78', 'groupId': 'OG001'}]}]}, {'title': 'Pain/Discomfort (Week 4)', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.77', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.81', 'groupId': 'OG001'}]}]}, {'title': 'Pain/Discomfort (Week 16)', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '0.93', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.92', 'groupId': 'OG001'}]}]}, {'title': 'Anxiety/Depression (Week 4)', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.74', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '0.79', 'groupId': 'OG001'}]}]}, {'title': 'Anxiety/Depression (Week 16)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.84', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '0.91', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and week 4 and 16', 'description': "The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.", 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'OG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.48', 'spread': '6.489', 'groupId': 'OG000'}, {'value': '-1.09', 'spread': '6.413', 'groupId': 'OG001'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '325', 'groupId': 'OG000'}, {'value': '325', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.46', 'spread': '8.196', 'groupId': 'OG000'}, {'value': '-0.88', 'spread': '8.177', 'groupId': 'OG001'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '326', 'groupId': 'OG000'}, {'value': '326', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.15', 'spread': '7.761', 'groupId': 'OG000'}, {'value': '-1.59', 'spread': '7.645', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and week 4, 12, and 16', 'description': 'The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Randomized population. Only participants with data available at the timepoint were analyzed.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'FG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'FG002', 'title': 'Active Treatment Period - Deucravacitinib 6 mg QD', 'description': 'Participants earlier randomized to Deucravacitinib 6 mg QD arm in Placebo-Controlled period continued to receive 6 mg deucravacitinib tablet orally QD till Week 52 during Active Treatment period.'}, {'id': 'FG003', 'title': 'Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD', 'description': 'Participants earlier randomized to Placebo arm in Placebo-Controlled period received 6 mg deucravacitinib tablet orally QD till Week 52 during Active Treatment period.'}], 'periods': [{'title': 'Pre-Treatment Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '336'}, {'groupId': 'FG001', 'numSubjects': '334'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '332'}, {'groupId': 'FG001', 'numSubjects': '333'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'OTHER REASONS', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'PARTICIPANT WITHDREW CONSENT', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}, {'title': 'Placebo-Controlled Treatment Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '332'}, {'groupId': 'FG001', 'numSubjects': '333'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '309'}, {'groupId': 'FG001', 'numSubjects': '306'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '23'}, {'groupId': 'FG001', 'numSubjects': '27'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'PARTICIPANT REQUEST TO DISCONTINUE STUDY TREATMENT', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'PARTICIPANT WITHDREW CONSENT', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '10'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'ADMINISTRATIVE REASONS BY SPONSOR', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Other reasons', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}, {'title': 'Active Treatment Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '309'}, {'groupId': 'FG003', 'numSubjects': '306'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '168'}, {'groupId': 'FG003', 'numSubjects': '160'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '141'}, {'groupId': 'FG003', 'numSubjects': '146'}]}], 'dropWithdraws': [{'type': 'OTHER REASONS', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '3'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '5'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '8'}]}, {'type': 'PARTICIPANT REQUEST TO DISCONTINUE STUDY TREATMENT', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}]}, {'type': 'PARTICIPANT WITHDREW CONSENT', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '11'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}]}, {'type': 'POOR/NON-COMPLIANCE', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'ADMINISTRATIVE REASONS BY SPONSOR', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}]}, {'type': 'ONGOING Treatment', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '117'}, {'groupId': 'FG003', 'numSubjects': '114'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '336', 'groupId': 'BG000'}, {'value': '334', 'groupId': 'BG001'}, {'value': '670', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo-Controlled Period - Deucravacitinib 6 mg QD', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered 6 mg of deucravacitinib tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'BG001', 'title': 'Placebo-Controlled Period - Placebo', 'description': 'Participants with Active Psoriatic Arthritis who are naive to biologic disease anti-rheumatic drugs were administered placebo tablet orally once daily (QD) from Week 1 till Week 16 during Placebo-Controlled treatment period.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '51.7', 'spread': '12.52', 'groupId': 'BG000'}, {'value': '52.3', 'spread': '12.32', 'groupId': 'BG001'}, {'value': '52.0', 'spread': '12.41', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '164', 'groupId': 'BG000'}, {'value': '170', 'groupId': 'BG001'}, {'value': '334', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '172', 'groupId': 'BG000'}, {'value': '164', 'groupId': 'BG001'}, {'value': '336', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '101', 'groupId': 'BG000'}, {'value': '94', 'groupId': 'BG001'}, {'value': '195', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '165', 'groupId': 'BG000'}, {'value': '165', 'groupId': 'BG001'}, {'value': '330', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '70', 'groupId': 'BG000'}, {'value': '75', 'groupId': 'BG001'}, {'value': '145', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'WHITE', 'categories': [{'measurements': [{'value': '263', 'groupId': 'BG000'}, {'value': '279', 'groupId': 'BG001'}, {'value': '542', 'groupId': 'BG002'}]}]}, {'title': 'BLACK OR AFRICAN AMERICAN', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}, {'title': 'AMERICAN INDIAN OR ALASKA NATIVE', 'categories': [{'measurements': [{'value': '17', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '36', 'groupId': 'BG002'}]}]}, {'title': 'OTHER', 'categories': [{'measurements': [{'value': '27', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '48', 'groupId': 'BG002'}]}]}, {'title': 'CHINESE', 'categories': [{'measurements': [{'value': '24', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '38', 'groupId': 'BG002'}]}]}, {'title': 'ASIAN OTHER', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2024-05-06', 'size': 13936135, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2025-09-02T09:31', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 670}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2021-07-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2027-06-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-10-08', 'studyFirstSubmitDate': '2021-05-28', 'resultsFirstSubmitDate': '2025-09-02', 'studyFirstSubmitQcDate': '2021-05-28', 'lastUpdatePostDateStruct': {'date': '2025-10-24', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2025-10-08', 'studyFirstPostDateStruct': {'date': '2021-06-01', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-10-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2024-09-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With ACR 20 Response at Week 16', 'timeFrame': 'Week 16', 'description': 'The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.'}, {'measure': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'timeFrame': 'Week 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.'}, {'measure': 'Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16', 'timeFrame': 'Week 16', 'description': 'Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.'}, {'measure': 'Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16', 'timeFrame': 'Week 16', 'description': 'Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:\n\n1. Tender joint count \\<= 1\n2. Swollen joint count \\<=1\n3. Psoriasis Area and Severity Index (PASI) \\<= 1 or body surface area (BSA) \\<= 3%\n4. Patient assessment of psoriatic arthiritis (PsA) pain \\<= 15\n5. Patient Global Assessment of PsA disease activity \\<= 20\n6. HAQ-DI \\<= 0.5\n7. Tender enthesial points \\<= 1'}, {'measure': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one\'s ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.'}, {'measure': 'Percentage of Participants Meeting Dactylitis Resolution at Week 16', 'timeFrame': 'Week 16', 'description': 'Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.'}, {'measure': 'Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.'}, {'measure': 'Percentage of Participants With ACR 20 Response up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12, and 16', 'description': 'The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.'}, {'measure': 'Percentage of Participants With ACR 50 Response up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12, and 16', 'description': 'The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.'}, {'measure': 'Percentage of Participants With ACR 70 Response up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12, and 16', 'description': 'The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16', 'timeFrame': 'Baseline and Week 2, 4, 8, 12, and 16', 'description': 'HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.'}, {'measure': 'Percentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline', 'timeFrame': 'Baseline and Week 2, 4, 8, 12, and 16', 'description': 'HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.'}, {'measure': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.'}, {'measure': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.'}, {'measure': "Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline", 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.'}, {'measure': 'Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.'}, {'measure': 'Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \\\\\\[R\\\\\\]/left \\\\\\[L\\\\\\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.'}, {'measure': 'Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16', 'timeFrame': 'Week 4, 8, 12, and 16', 'description': 'Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:\n\n1. Tender joint count \\<= 1\n2. Swollen joint count \\<=1\n3. Psoriasis Area and Severity Index (PASI) \\<= 1 or body surface area (BSA) \\<= 3%\n4. Patient assessment of psoriatic arthiritis (PsA) pain \\<= 15\n5. Patient Global Assessment of PsA disease activity \\<= 20\n6. HAQ-DI \\<= 0.5\n7. Tender enthesial points \\<= 1'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.'}, {'measure': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one\'s ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.'}, {'measure': 'Percentage of Participants Meeting Dactylitis Resolution up to Week 16', 'timeFrame': 'Week 4, 8, 12 and 16', 'description': 'Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.'}, {'measure': 'Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.'}, {'measure': 'Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\\\\[cm\\\\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.'}, {'measure': 'Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\\\\[cm\\\\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.'}, {'measure': 'Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\\\\[cm\\\\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.'}, {'measure': 'Percentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.'}, {'measure': 'Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16', 'timeFrame': 'Baseline and Week 2, 4, 8, 12 and 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\\\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\\\\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.'}, {'measure': 'Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\\\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\\\\>5.1=high disease activity.'}, {'measure': 'Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\\\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\\\\>5.1=high disease activity.'}, {'measure': 'Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.'}, {'measure': 'Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16', 'timeFrame': 'Baseline and Week 4, 8, 12 and 16', 'description': 'Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.'}, {'measure': 'Percentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': "The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity"}, {'measure': 'Percentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16', 'timeFrame': 'Week 2, 4, 8, 12 and 16', 'description': 'BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\\* standard deviation of the paired differences of change from baseline/ square root of (2\\*k); k is the number of reviewers and is default to 2 in this study.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\\* standard deviation of the paired differences of change from baseline/ square root of (2\\*k); k is the number of reviewers and is default to 2 in this study.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16', 'timeFrame': 'Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\\* standard deviation of the paired differences of change from baseline/ square root of (2\\*k); k is the number of reviewers and is default to 2 in this study.'}, {'measure': 'Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.'}, {'measure': 'Change From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16', 'timeFrame': 'Baseline and Week 4, 12 and 16', 'description': 'SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.'}, {'measure': 'Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16', 'timeFrame': 'Baseline and week 16', 'description': 'WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.'}, {'measure': 'Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16', 'timeFrame': 'Baseline and week 4 and 16', 'description': "The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement."}, {'measure': 'Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16', 'timeFrame': 'Baseline and week 4, 12, and 16', 'description': 'The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Biologic-Naive', 'BMS-986165', 'Deucravacitinib', 'Disease-modifying Anti-rheumatic Drugs', 'DMARDs', 'Joint Disease', 'Psoriatic Arthritis', 'PsA'], 'conditions': ['Psoriatic Arthritis']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html', 'label': 'BMS Clinical Trial Information'}, {'url': 'https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT04908202.html', 'label': 'BMS Clinical Trial Patient Recruiting'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria\n\n* Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening.\n* Meets the Classification Criteria for Psoriatic Arthritis at Screening.\n* Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening.\n* Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1.\n* Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening.\n* ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading.\n* Must have completed the week 52 treatment for the optional open-label long-term extension period.\n\nExclusion Criteria\n\n* Nonplaque psoriasis at screening or day 1.\n* Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis.\n* History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).\n* Active fibromyalgia.\n* Received an approved or investigational biologic therapy for the treatment of PsA or PsO.\n* Other protocol-defined Inclusion/Exclusion criteria apply.'}, 'identificationModule': {'nctId': 'NCT04908202', 'briefTitle': 'A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bristol-Myers Squibb'}, 'officialTitle': 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs', 'orgStudyIdInfo': {'id': 'IM011-054'}, 'secondaryIdInfos': [{'id': '2023-506256-25', 'type': 'OTHER', 'domain': 'EU Trial Number'}, {'id': 'U1111-1259-9443', 'type': 'REGISTRY', 'domain': 'WHO'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Deucravacitinib', 'interventionNames': ['Drug: Deucravacitinib']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'Deucravacitinib', 'type': 'DRUG', 'otherNames': ['BMS-986165'], 'description': 'Specified dose on specified days', 'armGroupLabels': ['Deucravacitinib']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Specified dose on specified days', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85297', 'city': 'Gilbert', 'state': 'Arizona', 'country': 'United States', 'facility': 'Local Institution - 0197', 'geoPoint': {'lat': 33.35283, 'lon': -111.78903}}, {'zip': '72401', 'city': 'Jonesboro', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Local Institution - 0188', 'geoPoint': {'lat': 35.8423, 'lon': -90.70428}}, {'zip': '92335', 'city': 'Fontana', 'state': 'California', 'country': 'United States', 'facility': 'Local Institution - 0168', 'geoPoint': {'lat': 34.09223, 'lon': -117.43505}}, {'zip': '92835', 'city': 'Fullerton', 'state': 'California', 'country': 'United States', 'facility': 'Local Institution - 0199', 'geoPoint': {'lat': 33.87029, 'lon': -117.92534}}, {'zip': '95815', 'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'Local Institution - 0038', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'zip': '91360', 'city': 'Thousand Oaks', 'state': 'California', 'country': 'United States', 'facility': 'Cohen Medical Centers', 'geoPoint': {'lat': 34.17056, 'lon': -118.83759}}, {'zip': '80230', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'Local Institution - 0170', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '33765', 'city': 'Clearwater', 'state': 'Florida', 'country': 'United States', 'facility': 'Local Institution - 0195', 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'zip': '33063', 'city': 'Margate', 'state': 'Florida', 'country': 'United States', 'facility': 'Local Institution - 0272', 'geoPoint': {'lat': 26.24453, 'lon': -80.20644}}, {'zip': '33014', 'city': 'Miami Lakes', 'state': 'Florida', 'country': 'United States', 'facility': 'Local Institution - 0082', 'geoPoint': {'lat': 25.90871, 'lon': -80.30866}}, {'zip': '30501', 'city': 'Gainesville', 'state': 'Georgia', 'country': 'United States', 'facility': 'Local Institution - 0171', 'geoPoint': {'lat': 34.29788, 'lon': -83.82407}}, {'zip': '83702', 'city': 'Boise', 'state': 'Idaho', 'country': 'United States', 'facility': 'Local Institution - 0087', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '60640', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Local Institution - 0080', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60467', 'city': 'Orland Park', 'state': 'Illinois', 'country': 'United States', 'facility': 'Local Institution - 0177', 'geoPoint': {'lat': 41.63031, 'lon': -87.85394}}, {'zip': '60195', 'city': 'Schaumburg', 'state': 'Illinois', 'country': 'United States', 'facility': 'Local Institution - 0178', 'geoPoint': {'lat': 42.03336, 'lon': -88.08341}}, {'zip': '40504', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Local Institution - 0083', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '21740', 'city': 'Hagerstown', 'state': 'Maryland', 'country': 'United States', 'facility': 'Local Institution - 0042', 'geoPoint': {'lat': 39.64176, 'lon': -77.71999}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Local Institution - 0198', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '65807', 'city': 'Springfield', 'state': 'Missouri', 'country': 'United States', 'facility': 'Local Institution - 0201', 'geoPoint': {'lat': 37.21533, 'lon': -93.29824}}, {'zip': '59901', 'city': 'Kalispell', 'state': 'Montana', 'country': 'United States', 'facility': 'Local Institution - 0268', 'geoPoint': {'lat': 48.19579, 'lon': -114.31291}}, {'zip': '08043', 'city': 'Voorhees Township', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Local Institution - 0186', 'geoPoint': {'lat': 40.4795, 'lon': -74.49062}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'University Hospitals Cleveland Medical Center-Dermatology', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '44130', 'city': 'Middleburg Heights', 'state': 'Ohio', 'country': 'United States', 'facility': 'Local Institution - 0028', 'geoPoint': {'lat': 41.36144, 'lon': -81.81291}}, {'zip': '43551', 'city': 'Perrysburg', 'state': 'Ohio', 'country': 'United States', 'facility': 'Local Institution - 0179', 'geoPoint': {'lat': 41.557, 'lon': -83.62716}}, {'zip': '73102', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Local Institution - 0182', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '97330', 'city': 'Corvallis', 'state': 'Oregon', 'country': 'United States', 'facility': 'Local Institution - 0185', 'geoPoint': {'lat': 44.56457, 'lon': -123.26204}}, {'zip': '29601', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Local Institution - 0175', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '38305', 'city': 'Jackson', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Local Institution - 0036', 'geoPoint': {'lat': 35.61452, 'lon': -88.81395}}, {'zip': '75013', 'city': 'Allen', 'state': 'Texas', 'country': 'United States', 'facility': 'Local Institution - 0172', 'geoPoint': {'lat': 33.10317, 'lon': -96.67055}}, {'zip': '79124', 'city': 'Amarillo', 'state': 'Texas', 'country': 'United States', 'facility': 'Local Institution - 0189', 'geoPoint': {'lat': 35.222, 'lon': -101.8313}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Local Institution - 0032', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '98021', 'city': 'Bothell', 'state': 'Washington', 'country': 'United States', 'facility': 'Local Institution - 0273', 'geoPoint': {'lat': 47.76232, 'lon': -122.2054}}, {'zip': '25801', 'city': 'Beckley', 'state': 'West Virginia', 'country': 'United States', 'facility': 'Local Institution - 0181', 'geoPoint': {'lat': 37.77817, 'lon': -81.18816}}, {'zip': '1111', 'city': 'Ciudad Autónoma de Buenos Aires', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Local Institution - 0213'}, {'zip': '1900', 'city': 'La Plata', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Local Institution - 0054', 'geoPoint': {'lat': -34.92126, 'lon': -57.95442}}, {'zip': '1878', 'city': 'Quilmes', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Local Institution - 0215', 'geoPoint': {'lat': -34.72065, 'lon': -58.25454}}, {'zip': 'X5004CDT', 'city': 'Córdoba', 'state': 'Córdoba Province', 'country': 'Argentina', 'facility': 'Local Institution - 0046', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': 'S2000', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'facility': 'Local Institution - 0196', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': '4000', 'city': 'San Miguel de Tucumán', 'state': 'Tucumán Province', 'country': 'Argentina', 'facility': 'Local Institution - 0047', 'geoPoint': {'lat': -26.81601, 'lon': -65.21051}}, {'zip': '1426', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Local Institution - 0194', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '1428', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Local Institution - 0169', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1427CCL', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Local Institution - 0192', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '5500', 'city': 'Mendoza', 'country': 'Argentina', 'facility': 'Local Institution - 0193', 'geoPoint': {'lat': -32.88946, 'lon': -68.84582}}, {'zip': '2606', 'city': 'Phillip', 'state': 'Australian Capital Territory', 'country': 'Australia', 'facility': 'Local Institution - 0220', 'geoPoint': {'lat': -35.35035, 'lon': 149.09151}}, {'zip': '2019', 'city': 'Botany', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Local Institution - 0137', 'geoPoint': {'lat': -33.94599, 'lon': 151.19591}}, {'zip': '2145', 'city': 'Westmead', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Local Institution - 0133', 'geoPoint': {'lat': -33.80383, 'lon': 150.98768}}, {'zip': '4102', 'city': 'Woolloongabba', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Local Institution - 0132', 'geoPoint': {'lat': -27.48855, 'lon': 153.03655}}, {'zip': '7000', 'city': 'Hobart', 'state': 'Tasmania', 'country': 'Australia', 'facility': 'Local Institution - 0211', 'geoPoint': {'lat': -42.87936, 'lon': 147.32941}}, {'zip': '3142', 'city': 'Camberwell', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Local Institution - 0136', 'geoPoint': {'lat': -37.84205, 'lon': 145.0694}}, {'zip': '29055450', 'city': 'Vitória', 'state': 'Espírito Santo', 'country': 'Brazil', 'facility': 'Local Institution - 0109', 'geoPoint': {'lat': -20.31944, 'lon': -40.33778}}, {'zip': '40150-150', 'city': 'Salvador', 'state': 'Estado de Bahia', 'country': 'Brazil', 'facility': 'Local Institution - 0001', 'geoPoint': {'lat': -12.97563, 'lon': -38.49096}}, {'zip': '36010-570', 'city': 'Juiz de Fora', 'state': 'Minas Gerais', 'country': 'Brazil', 'facility': 'Local Institution - 0002', 'geoPoint': {'lat': -21.76417, 'lon': -43.35028}}, {'zip': '80030110', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Local Institution - 0219', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '80440-080', 'city': 'Curitiba', 'state': 'Paraná', 'country': 'Brazil', 'facility': 'Local Institution - 0214', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '90480-000', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Local Institution - 0005', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '09060-870', 'city': 'Santo André', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Local Institution - 0108', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'zip': '4002', 'city': 'Plovdiv', 'state': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Local Institution - 0255', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '1463', 'city': 'Sofia', 'state': 'Sofia (stolitsa)', 'country': 'Bulgaria', 'facility': 'Local Institution - 0248', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '8000', 'city': 'Burgas', 'country': 'Bulgaria', 'facility': 'Local Institution - 0253', 'geoPoint': {'lat': 42.50651, 'lon': 27.46886}}, {'zip': '4000', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Local Institution - 0249', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '4000', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Local Institution - 0267', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '4001', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Local Institution - 0246', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '4001', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Local Institution - 0247', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '1505', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Local Institution - 0245', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1784', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Local Institution - 0259', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '9000', 'city': 'Varna', 'country': 'Bulgaria', 'facility': 'Local Institution - 0250', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'zip': '2531172', 'city': 'Viña del Mar', 'state': 'Región de Valparaíso', 'country': 'Chile', 'facility': 'Local Institution - 0261', 'geoPoint': {'lat': -33.02457, 'lon': -71.55183}}, {'zip': '0', 'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'facility': 'Local Institution - 0226', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7500571', 'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'facility': 'Local Institution - 0099', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7501126', 'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'facility': 'Local Institution - 0073', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7510047', 'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'facility': 'Local Institution - 0222', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7640881', 'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'facility': 'Local Institution - 0111', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '230071', 'city': 'Hefei', 'state': 'Anhui', 'country': 'China', 'facility': 'Local Institution - 0149', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '100005', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Local Institution - 0159', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '400010', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'country': 'China', 'facility': 'Local Institution - 0190', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '510120', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Local Institution - 0147', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '518020', 'city': 'Shenzhen', 'state': 'Guangdong', 'country': 'China', 'facility': 'Local Institution - 0143', 'geoPoint': {'lat': 22.54554, 'lon': 114.0683}}, {'zip': '116000', 'city': 'Dalian', 'state': 'Liaoning', 'country': 'China', 'facility': 'Local Institution - 0150', 'geoPoint': {'lat': 38.91222, 'lon': 121.60222}}, {'zip': '200040', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'Local Institution - 0146', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '322000', 'city': 'Yiwu', 'state': 'Zhejiang', 'country': 'China', 'facility': 'Local Institution - 0145', 'geoPoint': {'lat': 29.31506, 'lon': 120.07676}}, {'zip': '680003', 'city': 'Bucaramanga', 'state': 'Santander Department', 'country': 'Colombia', 'facility': 'Local Institution - 0071', 'geoPoint': {'lat': 7.125, 'lon': -73.11895}}, {'zip': '080020', 'city': 'Barranquilla', 'country': 'Colombia', 'facility': 'Local Institution - 0072', 'geoPoint': {'lat': 10.96854, 'lon': -74.78132}}, {'zip': '110221', 'city': 'Bogotá', 'country': 'Colombia', 'facility': 'Local Institution - 0069', 'geoPoint': {'lat': 4.60971, 'lon': -74.08175}}, {'zip': '111156', 'city': 'Bogotá', 'country': 'Colombia', 'facility': 'Local Institution - 0063', 'geoPoint': {'lat': 4.60971, 'lon': -74.08175}}, {'zip': '760042', 'city': 'Cali', 'country': 'Colombia', 'facility': 'Local Institution - 0070', 'geoPoint': {'lat': 3.43054, 'lon': -76.5199}}, {'zip': '050021', 'city': 'Medellín', 'country': 'Colombia', 'facility': 'Local Institution - 0094', 'geoPoint': {'lat': 6.245, 'lon': -75.57151}}, {'zip': '050034', 'city': 'Medellín', 'country': 'Colombia', 'facility': 'Local Institution - 0064', 'geoPoint': {'lat': 6.245, 'lon': -75.57151}}, {'zip': '250252', 'city': 'Zipaquirá', 'country': 'Colombia', 'facility': 'Local Institution - 0065', 'geoPoint': {'lat': 5.02208, 'lon': -74.00481}}, {'zip': '150 06', 'city': 'Prague', 'state': 'Praha 5', 'country': 'Czechia', 'facility': 'Local Institution - 0225', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '68601', 'city': 'Uherské Hradiště', 'state': 'Zlín', 'country': 'Czechia', 'facility': 'Local Institution - 0269', 'geoPoint': {'lat': 49.06975, 'lon': 17.45969}}, {'zip': '760 01', 'city': 'Zlín', 'state': 'Zlín', 'country': 'Czechia', 'facility': 'Local Institution - 0202', 'geoPoint': {'lat': 49.22645, 'lon': 17.67065}}, {'zip': '722 00', 'city': 'Ostrava', 'country': 'Czechia', 'facility': 'Local Institution - 0018', 'geoPoint': {'lat': 49.83465, 'lon': 18.28204}}, {'zip': '530 02', 'city': 'Pardubice', 'country': 'Czechia', 'facility': 'Local Institution - 0208', 'geoPoint': {'lat': 50.04075, 'lon': 15.77659}}, {'zip': '12850', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Local Institution - 0097', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '130 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Local Institution - 0017', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '70100', 'city': 'Kuopio', 'state': 'Northern Savonia', 'country': 'Finland', 'facility': 'Local Institution - 0089', 'geoPoint': {'lat': 62.89238, 'lon': 27.67703}}, {'zip': '00290', 'city': 'Helsinki', 'country': 'Finland', 'facility': 'Local Institution - 0013', 'geoPoint': {'lat': 60.16952, 'lon': 24.93545}}, {'zip': 'FI-20521', 'city': 'Turku', 'country': 'Finland', 'facility': 'Local Institution - 0119', 'geoPoint': {'lat': 60.45148, 'lon': 22.26869}}, {'zip': '37170', 'city': 'Chambray-lès-Tours', 'country': 'France', 'facility': 'Local Institution - 0077', 'geoPoint': {'lat': 47.33537, 'lon': 0.70286}}, {'zip': '34295', 'city': 'Montpellier', 'country': 'France', 'facility': 'Local Institution - 0075', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Local Institution - 0074', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '5700', 'city': 'Gyula', 'state': 'Bekes County', 'country': 'Hungary', 'facility': 'Local Institution - 0270', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}}, {'zip': '8000', 'city': 'Székesfehérvár', 'state': 'Fejér', 'country': 'Hungary', 'facility': 'Local Institution - 0049', 'geoPoint': {'lat': 47.18995, 'lon': 18.41034}}, {'zip': '1027', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Local Institution - 0023', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1027', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Local Institution - 0142', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1033', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Local Institution - 0026', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1036', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Local Institution - 0025', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1036', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Local Institution - 0203', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '8900', 'city': 'Zalaegerszeg', 'country': 'Hungary', 'facility': 'Local Institution - 0068', 'geoPoint': {'lat': 46.83695, 'lon': 16.84401}}, {'zip': 'F91 X012', 'city': 'Manorhamilton', 'state': 'Leitrim', 'country': 'Ireland', 'facility': 'Local Institution - 0104', 'geoPoint': {'lat': 54.30639, 'lon': -8.17611}}, {'zip': '4', 'city': 'Dublin', 'country': 'Ireland', 'facility': 'Local Institution - 0101', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': 'D15 X40D', 'city': 'Dublin', 'country': 'Ireland', 'facility': 'Local Institution - 0102', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': 'H91 TY80', 'city': 'Galway', 'country': 'Ireland', 'facility': 'Local Institution - 0103', 'geoPoint': {'lat': 53.27245, 'lon': -9.05095}}, {'zip': '16132', 'city': 'Genova', 'country': 'Italy', 'facility': 'Local Institution - 0066', 'geoPoint': {'lat': 45.21604, 'lon': 11.87211}}, {'zip': '27100', 'city': 'Pavia', 'country': 'Italy', 'facility': 'Local Institution - 0062', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '33100', 'city': 'Udine', 'country': 'Italy', 'facility': 'Local Institution - 0096', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'zip': '37134', 'city': 'Verona', 'country': 'Italy', 'facility': 'Local Institution - 0058', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}, {'zip': '25050', 'city': 'Saltillo', 'state': 'Coahuila', 'country': 'Mexico', 'facility': 'Local Institution - 0056', 'geoPoint': {'lat': 25.42595, 'lon': -100.97963}}, {'zip': '44610', 'city': 'Guadalajara', 'state': 'Jalisco', 'country': 'Mexico', 'facility': 'Local Institution - 0254', 'geoPoint': {'lat': 20.67738, 'lon': -103.34749}}, {'zip': '06720', 'city': 'Mexico City', 'state': 'Mexico City', 'country': 'Mexico', 'facility': 'Local Institution - 0057', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '78200', 'city': 'San Luis Potosí City', 'state': 'San Luis Potosí', 'country': 'Mexico', 'facility': 'Local Institution - 0128', 'geoPoint': {'lat': 22.15234, 'lon': -100.97135}}, {'zip': '97070', 'city': 'Mérida', 'state': 'Yucatán', 'country': 'Mexico', 'facility': 'Local Institution - 0061', 'geoPoint': {'lat': 20.967, 'lon': -89.62318}}, {'zip': '97070', 'city': 'Mérida', 'state': 'Yucatán', 'country': 'Mexico', 'facility': 'Local Institution - 0212', 'geoPoint': {'lat': 20.967, 'lon': -89.62318}}, {'zip': '31000', 'city': 'Chihuahua City', 'country': 'Mexico', 'facility': 'Local Institution - 0060', 'geoPoint': {'lat': 28.63528, 'lon': -106.08889}}, {'zip': '14080', 'city': 'Mexico City', 'country': 'Mexico', 'facility': 'Local Institution - 0209', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '91900', 'city': 'Veracruz', 'country': 'Mexico', 'facility': 'Local Institution - 0095', 'geoPoint': {'lat': 19.18095, 'lon': -96.1429}}, {'zip': '62-069', 'city': 'Dąbrówka', 'state': 'Greater Poland Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0231', 'geoPoint': {'lat': 52.38351, 'lon': 16.74359}}, {'zip': '30-149', 'city': 'Krakow', 'state': 'Lesser Poland Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0229', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '34-400', 'city': 'Nowy Targ', 'state': 'Lesser Poland Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0206', 'geoPoint': {'lat': 49.47783, 'lon': 20.03228}}, {'zip': '50-381', 'city': 'Wroclaw', 'state': 'Lower Silesian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0244', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '20-607', 'city': 'Lublin', 'state': 'Lublin Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0232', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '21-040', 'city': 'Świdnik', 'state': 'Lublin Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0230', 'geoPoint': {'lat': 51.21898, 'lon': 22.69621}}, {'zip': '05-830', 'city': 'Nadarzyn', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0233', 'geoPoint': {'lat': 52.09438, 'lon': 20.80776}}, {'zip': '02-665', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0235', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '02-672', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0243', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '05-200', 'city': 'Wołomin', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0236', 'geoPoint': {'lat': 52.34006, 'lon': 21.24207}}, {'zip': '80-382', 'city': 'Gdansk', 'state': 'Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0257', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '31-338', 'city': 'Gdynia', 'state': 'Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0234', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'zip': '42-202', 'city': 'Częstochowa', 'state': 'Silesian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0241', 'geoPoint': {'lat': 50.79646, 'lon': 19.12409}}, {'zip': '40-040', 'city': 'Katowice', 'state': 'Silesian Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0252', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '15-351', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Local Institution - 0114', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '30-002', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Local Institution - 0126', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '30-033', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Local Institution - 0127', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '31-501', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Local Institution - 0140', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '10-117', 'city': 'Olsztyn', 'country': 'Poland', 'facility': 'Local Institution - 0162', 'geoPoint': {'lat': 53.78376, 'lon': 20.49272}}, {'zip': '60-218', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Local Institution - 0113', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '60-702', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Local Institution - 0239', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '60-773', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Local Institution - 0112', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '00-874', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Local Institution - 0204', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '02-118', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Local Institution - 0205', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '03-291', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Local Institution - 0125', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '52-210', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Local Institution - 0210', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '90-368', 'city': 'Lodz', 'state': 'Łódź Voivodeship', 'country': 'Poland', 'facility': 'Local Institution - 0238', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '011172', 'city': 'Bucharest', 'state': 'București', 'country': 'Romania', 'facility': 'Local Institution - 0090', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '020125', 'city': 'Bucharest', 'state': 'București', 'country': 'Romania', 'facility': 'Local Institution - 0266', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '247065', 'city': 'Râmnicu Vâlcea', 'state': 'Vâlcea County', 'country': 'Romania', 'facility': 'Local Institution - 0010', 'geoPoint': {'lat': 45.1, 'lon': 24.36667}}, {'zip': '500283', 'city': 'Brasov', 'country': 'Romania', 'facility': 'Local Institution - 0012', 'geoPoint': {'lat': 45.64861, 'lon': 25.60613}}, {'zip': '011025', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Local Institution - 0167', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '014142', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Local Institution - 0260', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '030463', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Local Institution - 0263', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '11057', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Local Institution - 0184', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '400006', 'city': 'Cluj-Napoca', 'country': 'Romania', 'facility': 'Local Institution - 0011', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '200347', 'city': 'Craiova', 'country': 'Romania', 'facility': 'Local Institution - 0258', 'geoPoint': {'lat': 44.31667, 'lon': 23.8}}, {'zip': '700127', 'city': 'Iași', 'country': 'Romania', 'facility': 'Local Institution - 0262', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '700661', 'city': 'Iași', 'country': 'Romania', 'facility': 'Local Institution - 0265', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '700714', 'city': 'Iași', 'country': 'Romania', 'facility': 'Local Institution - 0264', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '300778', 'city': 'Timișoara', 'country': 'Romania', 'facility': 'Local Institution - 0091', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '650070', 'city': 'Kemerovo', 'country': 'Russia', 'facility': 'Local Institution', 'geoPoint': {'lat': 55.35417, 'lon': 86.10435}}, {'zip': '141060', 'city': 'Korolyov', 'country': 'Russia', 'facility': 'Local Institution', 'geoPoint': {'lat': 55.91417, 'lon': 37.82556}}, {'zip': '194214', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Local Institution', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '150003', 'city': 'Yaroslavl', 'country': 'Russia', 'facility': 'Local Institution', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'zip': '15006', 'city': 'A Coruña', 'country': 'Spain', 'facility': 'Local Institution - 0021', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'zip': '14004', 'city': 'Córdoba', 'country': 'Spain', 'facility': 'Local Institution - 0022', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Local Institution - 0019', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '08208', 'city': 'Sabadell', 'country': 'Spain', 'facility': 'Local Institution - 0020', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'zip': '833401', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Local Institution - 0123', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '704', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'Local Institution - 0121', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '710', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'Local Institution - 0122', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '110', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Local Institution - 0120', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '333423', 'city': 'Taoyuan District', 'country': 'Taiwan', 'facility': 'Local Institution - 0124', 'geoPoint': {'lat': 24.9896, 'lon': 121.3187}}, {'zip': 'SO16 6YD', 'city': 'Southampton', 'state': 'Hampshire', 'country': 'United Kingdom', 'facility': 'Local Institution - 0106', 'geoPoint': {'lat': 50.90395, 'lon': -1.40428}}, {'zip': 'CM227NR', 'city': 'Harlow', 'country': 'United Kingdom', 'facility': 'Local Institution - 0116', 'geoPoint': {'lat': 51.77655, 'lon': 0.11158}}, {'zip': 'ST6 7AG', 'city': 'Stoke-on-Trent', 'country': 'United Kingdom', 'facility': 'Local Institution - 0107', 'geoPoint': {'lat': 53.00415, 'lon': -2.18538}}], 'overallOfficials': [{'name': 'Bristol-Myers Squibb', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Bristol-Myers Squibb'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}